Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

Celgene building

Celgene’s triple multiple myeloma therapy clears phase III trial

The biotech says the combo hit its OPTIMISMM primary endpoint

- PMLiVE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions

- PMLiVE

Smart watch epilepsy monitor cleared by FDA

Approval could potentially clear the way for insurers to reimburse its cost

- PMLiVE

Christian Pangratz to head up Sterna Biologicals

He joins as CEO having previously served as senior VP for Vectura Group

Juno Therapeutics names Cindy Elkins as CIO

She joins the biopharma from Genentech, where she was VP of IT

The secret of success

It is becoming clear that success in pharma is associated with specialisation

- PMLiVE

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

Findings demonstrated a 71% reduction in cancer spreading and death

- PMLiVE

Roche unveils data for Tecentriq/Avastin combo in kidney cancer

Patients on the combo had a lengthier PFS than those on Pfizer’s Sutent

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo plus Yervoy aces phase III trial

The cancer drug combo met one of its primary endpoints in NSCLC patients

- PMLiVE

Astellas strengthens US and Canadian leadership team

Steve Sabus, Lynn Gerber and Kevin O’Keefe are promoted to new roles

Celgene’s CEO Mark Alles is appointed as chairman

He succeeds Bob Hugin who is retiring from the pharma firm

- PMLiVE

Allergan’s Avycaz breaks Gram-negative pneumonia antibiotic drought

Becomes the first new drug to treat the condition in over 15 years

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links